The Manila Times

AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors

AB Science SA (Euronext - FR0010557264 - AB) announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast ...
Business Insider

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

AB SCIENCE ANNOUNCES THE INITIATION OF COVERAGE OF ITS STOCK BY MAXIM GROUP WITH A TARGET PRICE OF EUR 4.0 PER SHARE Paris, December 18, 2025, 7.15pm CET AB Science SA (Euronext - FR0010557264 - AB) ...
Business Insider

AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid ...

AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA Paris, 07 ...
Nasdaq

AB Science (ENXTPA:AB) Price Target Increased by 22.25% to 4.31

The average one-year price target for AB Science (ENXTPA:AB) has been revised to €4.31 / share. This is an increase of 22.25% from the prior estimate of €3.53 dated September 27, 2025. The price ...
FOX59 News

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

AB Science SA (Euronext - FR0010557264 - AB) today announced the publication of a new article on the preprint platform MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study ...